top of page
ASCEND is dedicated to revolutionizing cancer treatment through advanced technologies and a deep understanding of tumor biology. Our goal is to conduct a new evolutionary clinical trial that treats patients during multiple therapy lines by discovering emergent resistant traits and therapy biomarkers.
OUR VISION
Advanced Cancer Biomarkers
ASCEND-CRC emphasizes minimally invasive sampling by systematically collecting paired blood samples alongside tissue biopsies, allowing for parallel analysis using blood-based epigenetic and transcriptomic techniques. A central objective of the phase 1 study is to develop plasma-based, non-invasive biomarkers. This approach is intended to enable a shift from traditional reliance on tissue-derived biomarkers toward a comprehensive, blood-based predictive model. Ultimately, this will support real-time clinical decision-making and reduce the need for repeated tissue biopsies.
Personalized Therapy Recommendations
Ultimately, ASCEND-CRC represents a fundamental reimagining of how we approach advanced cancer, replacing a static, one-size-fits-all model with a dynamic, biomarker-guided framework tailored to the evolving biology of each patient’s disease. ASCEND-CRC advances the promise of precision medicine by matching the right drugs to the right patients, thereby increasing the likelihood that patients receive effective treatments and improving outcomes for those with metastatic cancers
Novel Biologic Insights
Furthermore, ASCEND-CRC will shape the introduction and evaluation of novel therapies. Patients assigned to standard-of-care strategies will undergo longitudinal sampling to analyze emerging resistance mechanisms as tumors evolve, enabling clinicians and researchers to collaboratively define the timing and predominant mechanisms of resistance. This proactive approach may eventually limit sampling to targeted assays that identify resistance pathways.
bottom of page